Related references
Note: Only part of the references are listed.Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab
Luis A. Perez de Llano et al.
ALLERGY (2020)
Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort
Clairelyne Dupin et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2020)
Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent
James G. Krings et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2019)
A case of chronic eosinophilic pneumonia in a patient treated with dupilumab
Francesco Menzella et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2019)
Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis
Karin Jonstam et al.
ALLERGY (2019)
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Klaus F. Rabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
M. Castro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Share Paper
